Author

Alexandra Gunchenko

Observed name: A Gunchenko

Institution: Merck & Co., Inc., Rahway, NJ, USA (United States)

Observed institution: Merck & Co., Inc., Rahway, NJ, USA (United States)

OpenAlex ID: A5062200767

A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours

2014 · I Brana, R Berger, et al. · British Journal of Cancer · 90

Rational molecularly targeted combinations: A parallel-arm phase I trial of the humanized anti-IGF-1R antibody dalotuzumab (D) in combination with the allosteric AKT inhibitor MK-2206 or the gamma secretase inhibitor MK-0752, in patients with advanced solid tumors.

2012 · Irene Brana, Jhanelle Elaine Gray, et al. · Journal of Clinical Oncology · 1

Works count: 2

Citation count: 91

H-index: 1

I10-index: 1